CareDx, Inc. (CDNA): who owns it and who trades it
As of Nov 16, 2026, CDNA insiders reported 41 open-market sales worth $19.7M and no purchases in the last 12 months, with 82% of the sale value made under pre-set 10b5-1 plans. The largest seller was John Walter Hanna JR (CEO), with $7.5M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling CareDx
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CDNA
228 funds and institutions reported CDNA shares worth $1.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.81M | 9.32% | $137M | +6% |
| State Street Corp | 2.47M | 4.78% | $70.4M | -11% |
| Vanguard Capital Management LLC | 2.20M | 4.25% | $62.6M | +2% |
| Deerfield Management Company, L.P. | 2.00M | 3.87% | $56.9M | -9% |
| ARK Investment Management LLC | 1.95M | 3.78% | $55.7M | -12% |
| Boston Partners | 1.94M | 3.75% | $55.2M | +3% |
| Bamco Inc | 1.94M | 3.75% | $55.2M | -42% |
| Gagnon Securities LLC | 1.77M | 3.43% | $50.5M | +1% |
| California State Teachers Retirement System | 1.55M | 3.01% | $54.5M | +3286% |
| Chevy Chase Trust Holdings, LLC | 1.44M | 2.78% | $41M | -4% |
| Geode Capital Management, LLC | 1.33M | 2.57% | $37.9M | +6% |
| Ophir Asset Management Pty Ltd | 1.26M | 2.45% | $36M | +28% |
| Renaissance Technologies LLC | 1.24M | 2.41% | $35.4M | +5% |
| Braidwell LP | 1.22M | 2.36% | $34.8M | -44% |
| First Eagle Investment Management, LLC | 1.20M | 2.32% | $34.1M | +108% |
| Sumitomo Mitsui Trust Group, Inc. | 1.19M | 2.31% | $34M | -19% |
| Blue Water Life Science Advisors, LP | 1.19M | 2.30% | $33.9M | +27% |
| Amova Asset Management Americas, Inc. | 1.19M | 2.30% | $33.8M | -19% |
| Dimensional Fund Advisors LP | 1.18M | 2.29% | $33.7M | -19% |
| D. E. Shaw & Co., Inc. | 1.14M | 2.20% | $32.4M | +30% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CDNA insiders reported $0 of open-market purchases and $19.7M of sales. 82% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Michael Goldberg | Director | Sale plan | 3,547 | $78.32 | $278K | Form 4 |
| Nov 12, 2026 | Michael Goldberg | Director | Sale plan | 8,024 | $79.32 | $636K | Form 4 |
| Nov 12, 2026 | Michael Goldberg | Director | Sale plan | 2,229 | $79.85 | $178K | Form 4 |
| Nov 12, 2026 | Keith Kennedy | CFO | Sale plan | 800 | $78.78 | $63K | Form 4 |
| Nov 12, 2026 | Keith Kennedy | CFO | Sale plan | 1,297 | $79.61 | $103K | Form 4 |
| Nov 10, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale plan | 2,996 | $80.47 | $241K | Form 4 |
| Nov 10, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale plan | 200 | $81.05 | $16.2K | Form 4 |
| Nov 10, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale plan | 900 | $83.33 | $75K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 28,256 | $76.55 | $2.2M | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 12,380 | $77.42 | $958K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 6,897 | $78.59 | $542K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 7,415 | $79.49 | $589K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 3,403 | $80.38 | $274K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 2,710 | $81.40 | $221K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 300 | $82.08 | $24.6K | Form 4 |
| Nov 5, 2026 | Keith Kennedy | CFO | Sale plan | 600 | $83.60 | $50.2K | Form 4 |
| Aug 5, 2026 | George Bickerstaff | Director | Sale | 20,000 | $46.29 | $926K | Form 4 |
| Aug 5, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale plan | 2,188 | $46.15 | $101K | Form 4 |
| Aug 5, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale plan | 500 | $46.75 | $23.4K | Form 4 |
| Aug 4, 2026 | Christine Cournoyer | Director | Sale plan | 16,000 | $46.94 | $751K | Form 4 |
| Aug 4, 2026 | Michael Goldberg | Director | Sale | 44,700 | $47.06 | $2.1M | Form 4 |
| Jul 16, 2026 | John Walter Hanna JR | CEO | Sale plan | 68,000 | $39.01 | $2.7M | Form 4 |
| Jul 16, 2026 | John Walter Hanna JR | CEO | Sale plan | 50,000 | $36.11 | $1.8M | Form 4 |
| Jul 16, 2026 | Hannah Valantine | Director | Sale plan | 100 | $36.55 | $3.7K | Form 4 |
| Jul 16, 2026 | Hannah Valantine | Director | Sale plan | 28,679 | $36.14 | $1M | Form 4 |
| Jun 29, 2026 | John Walter Hanna JR | CEO | Sale plan | 39,900 | $29.24 | $1.2M | Form 4 |
| Jun 26, 2026 | John Walter Hanna JR | CEO | Sale plan | 100 | $29.00 | $2.9K | Form 4 |
| Jun 15, 2026 | John Walter Hanna JR | CEO | Sale plan | 17,683 | $24.03 | $425K | Form 4 |
| Jun 15, 2026 | Hannah Valantine | Director | Sale plan | 12,103 | $23.11 | $280K | Form 4 |
| Jun 11, 2026 | John Walter Hanna JR | CEO | Sale plan | 21,998 | $24.02 | $528K | Form 4 |
| Jun 4, 2026 | John Walter Hanna JR | CEO | Sale plan | 4,835 | $24.00 | $116K | Form 4 |
| May 15, 2026 | Arthur A Torres | Director | Sale | 6,484 | $19.89 | $129K | Form 4 |
| May 14, 2026 | Arthur A Torres | Director | Sale | 4,086 | $20.97 | $85.7K | Form 4 |
| May 5, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale | 2,688 | $20.68 | $55.6K | Form 4 |
| Apr 16, 2026 | John Walter Hanna JR | CEO | Sale plan | 10,282 | $21.12 | $217K | Form 4 |
| Feb 3, 2026 | Jeffrey Adam Novack | Secretary and General Co | Sale | 4,441 | $20.56 | $91.3K | Form 4 |
| Jan 22, 2026 | John Walter Hanna JR | CEO | Sale plan | 19,280 | $21.16 | $408K | Form 4 |
| Jan 21, 2026 | John Walter Hanna JR | CEO | Sale plan | 200 | $21.00 | $4.2K | Form 4 |
| Jan 15, 2026 | John Walter Hanna JR | CEO | Sale plan | 10,156 | $21.05 | $214K | Form 4 |
| Dec 4, 2025 | Jeffrey Adam Novack | Secretary and General Co | Sale | 286 | $19.75 | $5.6K | Form 4 |
| Dec 4, 2025 | Jeffrey Adam Novack | Secretary and General Co | Sale | 7,007 | $19.15 | $134K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John Walter Hanna JR | President and CEO, Director | – | $7.5M | Jul 16, 2026 |
| Keith Kennedy | CFO & COO | – | $5M | Nov 12, 2026 |
| Michael Goldberg | Director | – | $3.2M | Nov 12, 2026 |
| Hannah Valantine | Director | – | $1.3M | Jul 16, 2026 |
| George Bickerstaff | Director | – | $926K | Aug 5, 2026 |
| Christine Cournoyer | Director | – | $751K | Aug 4, 2026 |
| Jeffrey Adam Novack | Secretary and General Counsel | – | $743K | Nov 10, 2026 |
| Arthur A Torres | Director | – | $215K | May 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CDNA short interest
High short interest. 13.7% of CDNA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.19M CDNA shares were sold short, 13.7% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 5.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.19M | 13.68% | +7% | 1.36M | 5.3 |
| Oct 15, 2026 | 6.72M | 12.98% | +2% | 1.49M | 4.5 |
| Sep 30, 2026 | 6.59M | 12.73% | +5% | 1.44M | 4.6 |
| Sep 15, 2026 | 6.30M | 12.17% | +8% | 1.00M | 6.3 |
| Aug 31, 2026 | 5.83M | 11.27% | +1% | 1.21M | 4.8 |
| Aug 14, 2026 | 5.79M | 11.19% | -6% | 1.15M | 5.0 |
| Jul 31, 2026 | 6.14M | 11.86% | -1% | 1.44M | 4.2 |
| Jul 15, 2026 | 6.19M | 11.98% | -26% | 797,456 | 7.8 |
| Jun 30, 2026 | 8.34M | 16.14% | -1% | 1.15M | 7.3 |
| Jun 15, 2026 | 8.43M | 16.33% | +32% | 784,954 | 10.8 |
| May 29, 2026 | 6.37M | 12.33% | -2% | 703,311 | 9.1 |
| May 15, 2026 | 6.51M | 12.60% | -6% | 574,540 | 11.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
CareDx company events
CareDx filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Sep 16, 2026DealAmended an earlier report. CareDx, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission reporting the completion of its acquisition of Naveris, Inc., a Delaware corporation. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jul 7, 2026DealCareDx, Inc. completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software to Eurobio Scientific S.A., pursuant to and subject to the terms… Filing
- Jun 15, 2026LeadershipCareDx, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- Apr 28, 2026AgreementCareDx, Inc. entered into an Agreement and Plan of Merger with Naveris, Inc., a Delaware corporation, Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, and Shareholder Representative Services LLC, solely in its capacity as the representative of the… Filing
- Apr 23, 2026LeadershipAmended an earlier report. As previously disclosed in the Original Report, on February 24, 2026, the Company appointed Keith Kennedy, the Company’s previous Chief Operating Officer, as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026. Filing
- Apr 16, 2026AgreementCareDx, Inc. entered into a Purchase Agreement with Eurobio Scientific S.A., pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to… Filing
- Feb 25, 2026LeadershipAmended an earlier report. The Board of Directors of the Company has appointed Keith Kennedy as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 18, 2025AnnouncementAn unopposed motion for the preliminary approval of settlement was filed after CareDx, Inc. reached an agreement in principle for a proposed settlement of a shareholder derivative litigation, captioned Edelman, et al., v. Filing
- Dec 15, 2025RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
CareDx financials
Famous investors that hold CDNA
5 of the 50 well-known investors we track reported holding CDNA in their latest 13F filing. The largest position is Cathie Wood's, worth $105M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 1.61M | $105M | 0.6% | -18% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.26M | $81.6M | 0.1% | +1% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.14M | $73.8M | 0.0% | +962% |
| Israel Englander · Millennium Management | Q3 2026 | 258,531 | $16.8M | 0.0% | +250% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 109,858 | $7.1M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CDNA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
Questions about CareDx, Inc. (CDNA) stock
Who owns the most CDNA stock?
The largest reported owner of CareDx, Inc. (CDNA) is BlackRock, Inc., with 9.3% of the company. In total, 228 funds and institutions reported holding CDNA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CDNA insiders buying or selling?
In the last 12 months, CDNA insiders reported no open-market purchases and 41 sales worth $19.7M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in CDNA?
As of Oct 30, 2026, 7.19M CDNA shares were sold short, 13.7% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 5.3 trading days (days to cover). See the history.
Which famous investors hold CDNA?
5 of the 50 well-known investors we track reported CDNA in their latest 13F filing, including Cathie Wood, Jim Simons, Ken Griffin. The largest position is worth $105M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.